HoldsUp

FoundMyFitness · 2015-08-11 · Rhonda Patrick (host), Tim Ferriss

Tim Ferriss on Ketosis, Microbiome, Lyme Disease, and Biomarkers

40 claims checked against research: 1 contradicted 10 overstated 6 needing context 21 supported 1 corroborated online 1 unverified

10

Overstated

0:10:01Rhonda Patrick (host)overstatedmoderate

A homozygous MTHFR polymorphism reduces the MTHFR enzyme's efficiency to roughly 10% to 20% of normal function.

"she is homozygous for MTHFR, meaning that she her MTHFR enzyme only produces about 10—is working at about 10 to 20% efficiency." (said at 0:10:01)

The speaker significantly overstates the degree of enzyme impairment caused by common homozygous MTHFR polymorphisms. Classic biochemical characterization of the common MTHFR C677T polymorphism demonstrates that homozygous individuals (TT genotype) retain approximately 30% to 50% of wild-type (CC) enzyme activity (or a reduction of roughly 50–70%), rather than functioning at only 10% to 20% efficiency. Severe loss of MTHFR activity (under 20% or down to 0–10%) is characteristic of rare inborn errors of folate metabolism causing homocystinuria, not common homozygous polymorphisms.

0:14:11Rhonda Patrick (host)overstatedhigh

Between 65% and 80% of individuals diagnosed with Alzheimer's disease carry at least one APOE4 allele.

"if you look at Alzheimer's, people with Alzheimer's, between 65 and 80% of all people who have Alzheimer's have one allele of APOE4." (said at 0:14:11)

The speaker overstates the prevalence of the APOE4 allele among individuals with Alzheimer's disease. Comprehensive systematic reviews and meta-analyses show that globally, approximately 49% (95% CI: 46.5–51.0%) of people diagnosed with Alzheimer's disease carry at least one APOE4 allele. While the carrier frequency varies by ancestry and geographic region—ranging from ~37% in Asian populations to ~58% in North America and ~61–64% in Northern Europe—it falls well short of the claimed 65% to 80% across all patients.

0:18:15Rhonda Patrick (host)overstatedlow

Blood biomarkers measuring inactive phosphorylated insulin receptor substrate 1 (IRS-1) can predict Alzheimer's disease diagnosis 10 years in advance with 100% accuracy.

"there is a biomarker that is present in blood that's called insulin receptor substrate 1, and it's IRS-1, and it's recently, very, very recently been shown to be a diagnostic for Alzheimer's 10 years in advance with 100% accuracy." (said at 0:18:15)

The claim references preliminary findings from a small 2015 proof-of-concept study (Kapogiannis et al., FASEB J) evaluating neural-derived plasma exosomes. In that initial study of 26 Alzheimer's disease (AD) patients, 22 preclinical cases sampled 1 to 10 years before diagnosis, and controls, discriminant modeling using phosphorylated insulin receptor substrate 1 (IRS-1) ratios achieved 100% classification accuracy in the small exploratory sample. However, describing this as an established diagnostic tool that predicts Alzheimer's 10 years in advance with 100% accuracy substantially overstates the evidence. When validated in larger longitudinal cohorts (such as the Baltimore Longitudinal Study of Aging cohort published in JAMA Neurology in 2019), biomarker models including exosomal IRS-1 demonstrated moderate predictive accuracy (e.g., test-set AUC of 80%, sensitivity of ~56%, and specificity of ~89%), rather than 100% diagnostic certainty.

0:19:55Rhonda Patrick (host)overstatedmoderate

Individuals with type 2 diabetes have approximately a twofold increased risk of developing Alzheimer's disease.

"because if you look at people, type 2 diabetic, so being type 2 diabetic, you have a twofold or so roughly increased chance of getting Alzheimer's." (said at 0:19:55)

Large systematic reviews and meta-analyses of prospective cohort studies consistently show that individuals with diabetes mellitus have a statistically significant increased risk of developing Alzheimer's disease. However, the magnitude of this increased risk is typically between 35% and 53% (pooled relative risk of ~1.36 to 1.53), which is substantially lower than the claimed twofold (~100% or 2.0-fold) increase.

0:01:18Tim Ferrissoverstatedlow

Intranasal vasopressin enhances short-term memory performance.

"when I was in college, I was reading up on the smart drug literature at the time, and it was purported to be very effective for boosting short-term memory. So you would take hits in each nostril, study whatever you have to study, and then quickly scurry off to the test before it sort of evaporated, right?" (said at 0:01:18)

Early clinical studies in the 1980s reported modest improvements in short-term and declarative memory tasks following intranasal administration of vasopressin or its analogues (such as lysine-vasopressin and DG-AVP) in healthy volunteers and clinical populations. However, systematic reviews and subsequent controlled human trials found inconsistent results across tasks. The evidence suggests vasopressin may selectively modulate attentional orienting and encoding rather than reliably boosting short-term memory capacity, and it does not enhance post-learning memory consolidation.

0:08:28Tim Ferrissoverstatedlow

Combining fasting with chemotherapy improves chemotherapy effectiveness and accelerates patient recovery.

"maybe that explains why fasting plus chemotherapy is very, very effective. For instance, people can recover faster from chemotherapy." (said at 0:08:28)

Preclinical animal models have demonstrated that short-term fasting or fasting-mimicking diets (FMD) can induce differential stress resistance, sensitizing cancer cells to chemotherapy while protecting healthy tissues. Small clinical trials (such as the phase II DIRECT trial in HER2-negative breast cancer) have reported preliminary signals of improved radiological and pathological response rates and reduced toxicity markers. However, systematic reviews of clinical trials conclude that current human evidence remains limited, heterogeneous, and insufficient to establish that fasting is highly effective or routinely accelerates patient recovery in clinical practice.

0:24:45Rhonda Patrick (host)overstatedmoderate

Supplementing with 2 grams of vitamin C per day lowers C-reactive protein levels.

"there were studies that were showing, you know, taking 2 grams of supplemental vitamin C a day with lowered C-reactive protein" (said at 0:24:45)

Systematic reviews and meta-analyses of randomized trials indicate that vitamin C supplementation can produce a modest reduction in circulating C-reactive protein (CRP) levels, particularly among individuals with elevated baseline CRP or younger age groups. However, the evidence does not demonstrate that a high dose of 2 grams per day specifically reduces CRP. In meta-analytic subgroup analyses, significant reductions in CRP were primarily observed at lower daily doses (such as less than 500 mg/day) rather than higher supplemental doses.

0:25:34Rhonda Patrick (host)overstatedlow

Supplemental antioxidants can negate or blunt some of the physiological benefits of intermittent fasting.

"So you think antioxidants could negate some of the benefits of say intermittent fasting? HOST: Yes, they can. And it's been shown that that can." (said at 0:25:34)

The claim that supplemental antioxidants can blunt or negate the benefits of intermittent fasting is an extrapolation of the mitohormetic stress-response concept. Intermittent fasting acts as a mild, transient cellular stressor (hormesis) that relies on reactive oxygen species (ROS) and nutrient-sensing pathways (such as AMPK, sirtuins, and NRF2) to trigger adaptive metabolic resilience. While high-dose antioxidant supplementation (such as vitamins C and E) has been demonstrated in human trials to blunt ROS signaling and mitigate training adaptations in exercise models, direct clinical evidence establishing that antioxidant supplements abolish or blunt the specific physiological adaptations of intermittent fasting in humans remains theoretical and largely unproven.

0:54:09Rhonda Patrick (host)overstatedlow

People with the APOE4 allele are significantly less likely to develop Alzheimer's disease if they exercise, with more intense exercise providing greater protection.

"people with APOE4 are much, much less likely to get Alzheimer's. If they exercise more intensely, the better." (said at 0:54:09)

Physical activity is associated with a reduced risk of Alzheimer's disease and cognitive decline, and some observational cohorts show beneficial cognitive associations among APOE ε4 carriers engaging in vigorous activity. However, claiming that APOE4 carriers are "much, much less likely" to develop Alzheimer's disease specifically with increasingly intense exercise overstates both the magnitude of effect and the certainty of the dose-response relationship. Large prospective cohort data demonstrate that physical activity lowers Alzheimer's risk broadly across genetic risk groups without a statistically significant interaction by APOE status, and substantial risk reduction occurs even at light-to-moderate activity levels. Furthermore, systematic reviews of randomized exercise interventions find only very low- to moderate-certainty evidence for differential cognitive benefits by APOE4 status.

0:48:15Tim Ferrissoverstatedvery low

Short-term fasting for as few as three days can trigger a reboot of the immune system.

"I was looking at it as basically a reboot for the immune system, even shorter fasts like three days." (said at 0:48:15)

The claim that a three-day fast triggers an immune system "reboot" originates primarily from preclinical rodent research and preliminary human trials led by Valter Longo and colleagues. In mice, 48 to 72 hours of prolonged fasting caused white blood cell depletion followed by hematopoietic stem cell-mediated regeneration and rejuvenation upon refeeding, driven by down-regulation of IGF-1 and PKA signaling. However, evidence demonstrating a complete "reboot" or functional renewal of the immune system in healthy humans following a 3-day fast remains preliminary, making the claim overstated when applied generally to humans.

  • partial: Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration … (Cell stem cell 2014) · cited 500x in the literature
    "Here, we show that prolonged fasting reduces circulating IGF-1 levels and PKA activity in various cell populations, leading to signal transduction changes in long-term hematopoietic stem cells (LT-HSCs) and niche cells that promote stress resistance, self-renewal, and lineage-balanced regeneration. Multiple cycles of fasting abated the immunosuppression and mortality caused by chemotherapy and reversed age-dependent myeloid-bias in mice, in agreement with preliminary data on the protection of lymphocytes from chemotoxicity in fasting patients." (abstract, passage verified)
    pubmedfull study (doi)

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.